TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25090173
Drug: Linkage group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linkage group (buprenorphine induction, intrahospital dose stabilization, and postdischarge transition to maintenance buprenorphine OAT)
Study: 22997755
Drug: Citoflavin included
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citoflavin included in the complex program of intensive therapy
Study: 10445787
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) 3 x 120 mg + Tetracycline (TET) 3 x 250 mg + Metronidazole (MET) 3 x 125 mg/day
Study: 11251357
Drug: Prolonged prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged prophylaxis with low-molecular-weight heparin (LMWH)
Study: 11251357
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of administering LMWH (including teaching self-administration and follow-up visit)
Study: 10534208
Drug: Trovafloxacin 200
Normalized name: trovafloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 200 mg once daily for 5 days
Study: 23322466
Drug: Tocilizumab-MTX 8
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tocilizumab-MTX 8 mg/kg
Study: 8944373
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily (OME40)
Study: 2936636
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2% miconazole nitrate and 5% benzoyl peroxide applied twice daily
Study: 25824852
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment by experts (CTBE)
Study: 19467175
Drug: Mometasone furoate,
Normalized name: Mometasone Furoate, 50 mcg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate, 200 mcg once daily
Study: 28403910
Drug: Jaungo and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jaungo and placebo ointment applied once a day for 3 weeks
Study: 15297081
Drug: Synbiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic preparation (Lactobacillus acidophilus La5, Bifidobacterium lactis Bb 12, Streptococcus thermophilus, Lactobacillus bulgaricus with oligofructose)
Study: 11979067
Drug: Single-dose nicotine
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose nicotine
Study: 21208922
Drug: No varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No varicella vaccine
Study: 389264
Drug: Ibuprofen administration
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen administration
Study: 3355619
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of encapsulated fish oil per day
Study: 3355619
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of encapsulated safflower oil (placebo) per day
Study: 2776141
Drug: Flosequinan 100
Normalized name: flosequinan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan 100 mg orally once daily for 3 days
Study: 10587284
Drug: Haloperidol 25
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol 25 mg/day + Lithium
Study: 3924286
Drug: Honey in
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey in oral rehydration solution
Study: 9020945
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus methylprednisolone (250 mg IV)
Study: 18290565
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors and steroids only (Control)
Study: 23374677
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg
Study: 7134228
Drug: Fluid monovalent
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid monovalent influenza A/New Jersey/8/76 vaccines (double the antigen content)
Study: 30151994
Drug: V- AS
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V- AS group (vonoprazan 20-mg bid, amoxicillin 750-mg bid, sitafloxacin 100-mg bid for 7 days)
Study: 8559949
Drug: Stopped light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopped light treatment early during winter (n = 6)
Study: 2706319
Drug: Marketing Suspension
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketing Suspension (MS)
Study: 7980076
Drug: nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine retard 20 mg
Study: 1827042
Drug: cilazapril 2.5
Normalized name: cilazapril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril 2.5 mg
Study: 9140802
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg once daily
Study: 7833497
Drug: Insulin at
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin at 50 microU/mL
Study: 17537539
Drug: SPLENDA Sucralose
Normalized name: Sucralose
DrugBank: Sucralose (DB15049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPLENDA Sucralose control (250 ml with water)
Study: 11709454
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment from general practitioner including patient education and drug treatment if necessary)
Study: 366722
Drug: benoxaprofen 200
Normalized name: fenoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: benoxaprofen 200 mg b.d. for three weeks
Study: 25210836
Drug: Biannual mass
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual mass azithromycin treatment (6 distributions)
Study: 22010915
Drug: Earlier-ART group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier-ART group (ART initiated within 4 weeks after the start of tuberculosis treatment, 214 patients)
Study: 7615781
Drug: Inhaled beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta 2 agonist alone
Study: 19755670
Drug: Sodium salicylate
Normalized name: Sodium Salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium salicylate (4.5 g/day)
Study: 19755670
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium salicylate (SS)
Study: 30901440
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplement (treatment group)
Study: 26577754
Drug: Etonogestrel (ENG)
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel (ENG) implant
Study: 17967219
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (10 mg)
Study: 21785860
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil
Study: 11564390
Drug: Omapatrilat 25
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 25 mg
Study: 30946283
Drug: Laparoscopic pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic pelvic organ prolapse suspension operation
Study: 11795452
Drug: Microwave treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave treatment
Study: 11119198
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac 2 mg.kg(‐1) following oral placebo premedication
Study: 11119198
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine premedication
Study: 29858418
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture and placebo medicine
Study: 19917888
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg daily
Study: 11288822
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine
Study: 17485422
Drug: Tocilizumab monotherapy
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks
Study: 14745142
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil
Study: 9433338
Drug: Fixed haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed haloperidol doses intended to achieve plasma levels of 8‐18 ng/ml
Study: 15452834
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus paclitaxel (two dose levels)
Study: 15179409
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g powder without hyperforin, tea, juice, oil extract, hyperforin-free extract (Ze 117), low daily doses of hyperforin-containing Hypericum powder (1 g, 0.5 g)
Study: 7019641
Drug: Terbutaline sulphate
Normalized name: Terbutaline sulphate
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline sulphate 0.5 mg via metered aerosol
Study: 7019641
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered theophylline 5 mg/kg
Study: 2038732
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terbutaline and theophylline
Study: 3328284
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg x 2 for 4-8 weeks (up to 12 weeks for gastric ulcers)
Study: 27917729
Drug: Topical triamcinolone
Normalized name: triamcinolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical triamcinolone
Study: 15484727
Drug: Pea meal
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pea meal diet (200 g/kg)
Study: 2661658
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg two times daily
Study: 27917729
Drug: Oral dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dapsone
Study: 18940558
Drug: Botulinum injection
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum injection followed by physiotherapy
Study: 12689686
Drug: Ibandronate 2.5
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2.5 mg taken 60 minutes before breakfast
Study: 1954661
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng compound liquor (treated group)
Study: 21219551
Drug: Artesunate and
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate and Mefloquine (fixed dose combination)
Study: 9137798
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate 480 mg/day
Study: 2493302
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa 5 megaunits (MU) daily for one week, reducing to 5 MU thrice weekly for seven weeks, then 3 MU thrice weekly for eight weeks
Study: 16834525
Drug: Drug laboratory
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug laboratory monitoring alerts within the CPOE system
Study: 2442610
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (placebo) 0.5 ml/kg body weight, administered intramuscularly at 2, 6, and 10 months of age.
Study: 16824993
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD) infusion (7.5 microg/kg/min)
Study: 10708231
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (timolol maleate, carteolol, metipranolol)
Study: 30139340
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous infusion of somatostatin for 6 days
Study: 31100514
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 6 days
Study: 27725233
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid (HA) injection (10 cc)
Study: 2856773
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg once daily
Study: 10322831
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of Xuefu Zhuyu decoction and move stripe field radiation
Study: 12665756
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil solution administered intraluminally
Study: 30852486
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Traditional Chinese medicine Zhiyi decoction)
Study: 3403422
Drug: Hot air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot air inhalation (ambient air)
Study: 30400937
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA) 100 mg/d, prescribed at night, starting from early pregnancy (12-20 weeks of gestation) until 34 weeks of gestation.
Study: 27443451
Drug: Twice-daily treatment
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily treatment of valaciclovir
Study: 24355050
Drug: β-carotene from
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-carotene from dietary supplements
Study: 24355050
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C from dietary supplements
Study: 24355050
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E from dietary supplements
Study: 24516261
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day therapy with atorvastatin 10 mg and fenofibrate 160 mg
Study: 22545737
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for adherence and depression (CBT-AD)
Study: 24245566
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus renal-artery stenting
Study: 22722513
Drug: Conventional switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional switch strategy (4 further weeks on escitalopram 10 to 20 mg/d, then switch to duloxetine if nonresponse)
Study: 9260074
Drug: Intranasal cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal cocaine HCl (100 mg)
Study: 21310305
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of mixed fibers
Study: 12452319
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (Ang II) infusion at a constant dose of 50 ng/min
Study: 29482026
Drug: Reduced fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced fluid output, weight loss, and diuretic efficiency (DE)
Study: 12452319
Drug: Noradrenaline (NA)
Normalized name: noradrenaline hydrochloride
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noradrenaline (NA) infusion with increasing doses (2‐256 ng/min)
Study: 3049846
Drug: Nifedipine 80
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine 80 mg/day
Study: 17364311
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (40 mg)
Study: 27863271
Drug: Combined hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined hormonal oral pill
Study: 2007359
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 micrograms four times daily
Study: 6535339
Drug: Discontinue medication
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue medication with no dietary intervention
Study: 6535339
Drug: Discontinue medication
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue medication and reduce weight
Study: 6535339
Drug: Discontinue medication
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue medication and reduce sodium
Study: 29974637
Drug: Vehicle administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle administration
Study: 20509823
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g fibre (fructose-oligosaccharides) diet supplementation
Study: 18417246
Drug: Platinum-based combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based combination chemotherapy (3 chemotherapy courses)
Study: 30407932
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of rTMS treatment based on cBEI
Study: 12065457
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 1000 mg, four injections every 6 weeks plus daily oral levonorgestrel (LNG, 250 microg)
Study: 6271000
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g citrus pectin added to a mixed low fiber diet
Study: 12095064
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% gel
Study: 16519625
Drug: Vitamin K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K1 10 mg per day injection intramuscularly or intravenously for 2‐7 days (n = 40)
Study: 27196626
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLL)
Study: 22777041
Drug: ST-246 400
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-246 400 mg and 600 mg
Study: 20035387
Drug: Risk-adapted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk-adapted treatment approach
Study: 24742226
Drug: Yuzu scent
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [The creme shop BT21 MOISTURIZING SANITIZERSpray YUZU SCENTED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzu scent inhalation
Study: 22704121
Drug: Pelvic plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic plexus block (2.5 ml lidocaine 1% plus naropine 0.75%) plus intrarectal local anesthesia (lidocaine 1.5%-nifedipine 0.3% cream)
Study: 28355323
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy based on reflex stimulation (RPT)
Study: 16552809
Drug: Diuretics alone
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics alone (group 2)
Study: 23949578
Drug: Albuterol administration
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol administration
Study: 16803420
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 or 10 mg/day
Study: 17703632
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (Apidra®)
Study: 18238788
Drug: Control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatments